Epitope
Executive Summary
Beaverton, Oregon-based company signs agreement with Smith Kline & French to develop Epitope's proprietary compounds for the treatment of protozoan-caused diseases, including malaria. In return for funding animal and human clinical trials and the purchase of an equity position in Epitope, SK&F receives exclusive world-wide marketing rights except in the U.S., where the drugs will be co-marketed.